Drug Trial Radar · NCT05907291
Evaluate the Safety, Efficacy, and Pharmacokinetics of CRN04894 in Participants With Congenital Adrenal Hyperplasia (TouCAHn)
Last checked: Nov 19, 2026Latest source record: Sep 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
38
Actual
Start
Jul 3, 2023
Primary completion
Aug 22, 2025
Study completion Aug 22, 2025
Sponsor
- Lead sponsor
- Crinetics Pharmaceuticals Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 18, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 16 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this Phase 2, open-label, sequential dose cohort study is to evaluate the safety, efficacy, and pharmacokinetics (PK) of atumelnant (CRN04894) in participants with classic congenital adrenal hyperplasia (CAH) caused by 21-hydroxylase deficiency.
Conditions
- Congenital Adrenal Hyperplasia
- Classic Congenital Adrenal Hyperplasia
Interventions
atumelnant (CRN04894)Drug
Atumelnant is an orally active nonpeptide melanocortin 2 receptor (MC2R) or adrenocorticotropic hormone (ACTH) antagonist.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Morning (Before 11:00) Serum Androstenedione (A4) PM DosingTime frame: Baseline and Week 12
- Change From Baseline in Morning (Before 11:00) Serum Androstenedione (A4) AM DosingTime frame: Baseline and Week 12
- Number of Participants Reporting of Treatment-emergent Adverse Events (TEAEs), Serious TEAEs, and Adverse Events Leading to Discontinuation Throughout the StudyTime frame: From Day 1 to Up to Week 16 (End of study)
Locations
27 sites in 7 countries. Site status is shown where the registry gives one.
Crinetics Study Site
Pasadena, California
Crinetics Study Site
Ann Arbor, Michigan
Crinetics Study Site
Minneapolis, Minnesota
Crinetics Study Site
St Louis, Missouri
Crinetics Study Site
Morehead City, North Carolina
Crinetics Study Site
Cleveland, Ohio
Crinetics Study Site
Philadelphia, Pennsylvania
Crinetics Study Site
East Providence, Rhode Island
Crinetics Study Site
Buenos Aires, Argentina
Crinetics Study Site
Córdoba, Córdoba Province, Argentina
Crinetics Study Site
Rio de Janeiro, Brazil
Crinetics Study Site
Rio de Janeiro, Brazil
Crinetics Study Site
São Paulo, Brazil
Crinetics Study Site
São Paulo, Brazil
Crinetics Study Site
Curitiba, Paraná, Brazil
Crinetics Study Site
Porto Alegre, Rio Grande do Sul, Brazil
Crinetics Study Site
Botucatu, São Paulo, Brazil
Crinetics Study Site
Ribeirão Preto, São Paulo, Brazil
Crinetics Study Site
Munich, Bavaria, Germany
Crinetics Study Site
Bangalore, Karnataka, India
Crinetics Study Site
Vellore, Tamil Nadu, India
Crinetics Study Site
Naples, Italy
Crinetics Study Site
Roma, Italy
Crinetics Study Site
Rozzano, Italy
Crinetics Study Site
London, United Kingdom
Crinetics Study Site
Sheffield, South Yorkshire, United Kingdom
Crinetics Study Site
Coventry, West Midlands, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.